ELV logo

Elevance Health, Inc. Stock Price

NYSE:ELV Community·US$92.3b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 214 Fair Values set on narratives written by author

ELV Share Price Performance

US$426.79
90.58 (26.94%)
US$436.52
Fair Value
US$426.79
90.58 (26.94%)
2.2% undervalued intrinsic discount
US$436.52
Fair Value
Price US$426.79
AnalystConsensusTarget US$436.52
NateF US$390.54
AnalystHighTarget US$498.00

ELV Community Narratives

·
Fair Value US$436.52 2.2% undervalued intrinsic discount

ELV: Margin Recovery Will Drive Upside Despite ACA Headwinds And Premium Increases

0users have liked this narrative
0users have commented on this narrative
110users have followed this narrative
Fair Value
·
Fair Value US$390.54 9.3% overvalued intrinsic discount

ELV Market Outlook

1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
·
Fair Value US$498 14.3% undervalued intrinsic discount

Aging Trends And Digital Integration Will Expand Managed Care Markets

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
ELV logo
Elevance Health

ELV Market Outlook

Elevance Health, Inc. (NYSE: ELV) is a prominent player in the health benefits industry, offering a range of services including medical, pharmaceutical, dental, and behavioral health plans.Read more

View narrative
US$390.54
9.3% overvalued intrinsic discount
Fair Value
Revenue
6.79% p.a.
Profit Margin
3.69%
Future PE
13.33x
Price in 2029
US$546.7
US$498
14.3% undervalued intrinsic discount
Revenue
2.34% p.a.
Profit Margin
3.42%
Future PE
16.22x
Price in 2029
US$611.49
US$331
28.9% overvalued intrinsic discount
Revenue
0.73% p.a.
Profit Margin
3.16%
Future PE
12.21x
Price in 2029
US$405.95

Trending Discussion

No trending discussion available.

Updated Narratives

ELV logo

ELV Market Outlook

Fair Value: US$390.54 9.3% overvalued intrinsic discount
8 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ELV logo

ELV: Stable Policy Backdrop And Medicaid Uncertainty Will Shape Margin Recovery

Fair Value: US$436.52 2.2% undervalued intrinsic discount
110 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ELV logo

ELV: CMS Sanction Resolution And Stable Policy Backdrop Will Support Margin Recovery

Fair Value: US$498 14.3% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet and pays a dividend.

0 Risks
4 Rewards

Elevance Health, Inc. Key Details

US$200.4b

Revenue

US$148.5b

Cost of Revenue

US$51.9b

Gross Profit

US$46.6b

Other Expenses

US$5.2b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 15, 2026
24.14
25.89%
2.62%
72.3%
View Full Analysis

About ELV

Founded
2001
Employees
96615
CEO
Gail Boudreaux
WebsiteView website
www.elevancehealth.com

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Recent ELV News & Updates

Narrative Update Jul 14

ELV: Stable Policy Backdrop And Medicaid Uncertainty Will Shape Margin Recovery

Analysts have increased the Elevance Health fair value estimate from $418.67 to $436.52, as higher price targets across the Street cite constructive earnings expectations for healthcare services, steadier trends in Medicare Advantage and exchanges, and a more stable policy backdrop, partially offset by ongoing uncertainty around Medicaid performance. Analyst Commentary Recent research on Elevance Health points to a generally constructive tone, with many bullish analysts adjusting price targets higher while still flagging areas where execution and policy risk could affect valuation and growth.
Seeking Alpha Jul 11

Elevance Health: Defense For An Undervalued Price

Summary Elevance Health has outperformed the benchmark, rising 28% versus 11%, and I see further upside potential. ELV demonstrates steady top- and bottom-line growth, supporting a premium multiple and reinforcing management confidence. The insurance market's steady growth is a structural tailwind; if ELV maintains market share, it stands to benefit. Despite some risks, I continue to view ELV as undervalued with a solid capital structure and long-term bullish prospects. Read the full article on Seeking Alpha

Recent updates

No updates